Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in patients.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy that acts on BCR‑ABL positive leukemic cells, providing disease control in specific blood cancers.

- Chronic Myeloid Leukemia (CML) – chronic phase: reduces proliferation of malignant cells and improves survival. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): achieves disease control in patients with the BCR‑ABL fusion. - BCR‑ABL positive leukemias (general): provides a molecularly directed inhibition of the disease‑driving kinase.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may require fluid replacement. - Rash: skin irritation ranging from mild erythema to pruritus. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas requiring medical attention. - Hepatic toxicity: elevated liver enzymes indicating possible liver injury.

Nilotinib requires careful monitoring and patient education before and during therapy. - Cardiac monitoring: assess QT interval and correct electrolyte imbalances. - Hepatic function: evaluate liver enzymes regularly. - Hematologic surveillance: monitor complete blood counts for neutropenia or thrombocytopenia. - Drug interactions: avoid strong CYP3A4 inhibitors and QT‑prolonging agents. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nilotinib may interact with several concomitant medications, necessitating vigilance. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - QT‑prolonging drugs (e.g., amiodarone): heighten risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise concentrations. - Proton pump inhibitors: potential effect on gastric pH and drug uptake.